Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01250210 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control
A Phase 2 study of Ovulation Suppression, sponsored by Agile Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
- 11
- Study locations
NCT01250210: Completed Phase 2 study of Ovulation Suppression, sponsored by Agile Therapeutics.
NCT01250210 is a Phase 2 study of Ovulation Suppression that has completed, run by Agile Therapeutics. The registered enrollment target is 123 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01250210, a Phase 2 study of Ovulation Suppression, has completed, sponsored by Agile Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
- 11
- Study locations
Study Summary
Evaluate the adequacy of ovulation suppression, cycle control, and safety of three transdermal contraceptive delivery systems (TCDSs).
Primary Outcome
Ovulation suppression measured by possible ovulation. Possible ovulation is defined as cycles with greatest progesterone level ≥4.7 ng/mL across Cycles 1-3 combined for each Arm/Group. The following four primary analysis datasets are: Intent-to-treat (ITT): At least 1 study patch was applied and at least 1 progesterone measurement is available at 1 of the nominal data collection points. Complete progesterone: At least 1 study patch was applied and at least 3 progesterone measurements are avail
Conditions Studied
Interventions
- DRUG levonorgestrel and ethinyl estradiol
Study Locations (11)
Florida
- - Pembroke Pines
- - Tampa
North Carolina
- - Cary
- - Winston-Salem
Pennsylvania
- - Jenkintown
- - Philadelphia
Arizona
- - Tucson
California
- - San Diego
Colorado
- - Denver
Georgia
- - Sandy Springs
Tennessee
- - Bristol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
What the finished NCT01250210 record still lists
NCT01250210 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Ovulation Suppression appearing as the primary indexed condition, and to 1 intervention - of which levonorgestrel and ethinyl estradiol is the first listed.
NCT01250210 lists 11 locations in 8 states (Florida, North Carolina, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT01250210 about?
NCT01250210 is a clinical study titled "Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control". Evaluate the adequacy of ovulation suppression, cycle control, and safety of three transdermal contraceptive delivery systems (TCDSs).
What is the current status of trial NCT01250210?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2007-09. Estimated completion is 2008-02.
What conditions does trial NCT01250210 study?
This clinical trial studies the following conditions: Ovulation Suppression.
What interventions are being tested in trial NCT01250210?
The interventions under investigation include: levonorgestrel and ethinyl estradiol (DRUG).
Who is sponsoring clinical trial NCT01250210?
This trial is sponsored by Agile Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01250210 being conducted?
This trial has 11 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01250210's enrollment target sits among peer trials
123 564th of 2000 higher than 1,436 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia